Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U

    Track: Kidney Cancer
    Session Type: Controversies in Urology

    Controversies in Urology: Locally Advanced/Metastatic Kidney Cancer: Evolving Strategies in a Multidisciplinary Era

    Saturday, November 1, 2025
    14:00 - 15:30 GMT+0

      Co-Chair(s)

    • Carme Mir

      Urologist
      Fundacion Instituto Valenciano Oncologia, Spain

    • Sarah Psutka

      Associate Professor of Urology.
      University of Washington, United States

    Locally advanced/Metastatic kidney cancer (LA-RCC) presents a therapeutic challenge requiring multidisciplinary collaboration. This session will explore evolving surgical, systemic, and multimodal approaches, featuring state-of-the-art lectures followed by debates between urologists and oncologists on controversial aspects of management.

    Learning Objectives :

    At the end of this session, attendees should be able to:
    • Understand risk stratification for locally advanced RCC.
    • Evaluate the role of surgery vs. systemic therapy in multimodal management.
    • Debate the use of neoadjuvant and adjuvant therapy for optimizing patient outcomes.
    • Explore future biomarker-driven treatment strategies.

    Presentations:

    • 14:05 - 14:20 GMT+0
      Defining Locally Advanced RCC: Biology, Risk Stratification, and Outcomes:
      - TNM Staging & Risk Models (UISS, Leibovich, CARMENA Insights)
      - Role of Molecular Profiling in High-Risk Disease
      - Natural History and Recurrence Risks After Surgery

      Speaker: Hadi Radfar – Urology and Nephrology Research Center

    • 14:20 - 14:35 GMT+0
      Surgery for Locally Advanced RCC: How Far Can We Push the Limits?
      - Role of Radical Nephrectomy & Lymphadenectomy
      - Resection of Venous Tumor Thrombus (IVC Thrombus Management)
      - Challenges in Resecting Adrenal and Perinephric Invasion
      - Minimally Invasive vs. Open Approaches

      Speaker: Alessandro Volpe – University of Eastern Piedmont, Maggiore della Carità Hospital

    • 14:35 GMT+0
      Debate #1 Neoadjuvant Therapy Before Surgery: Ready for Primetime or Too Soon to Tell?
    • 14:35 - 14:45 GMT+0
      Position 1: Neoadjuvant Therapy is the Future for Locally Advanced RCC

      Speaker: Grant Stewart – Department of Surgery, University of Cambridge

    • 14:45 - 14:55 GMT+0
      Position 2: Neoadjuvant Therapy is Not Ready for Routine Use

      Speaker: Carme Mir – Fundacion Instituto Valenciano Oncologia

    • 14:55 - 15:00 GMT+0
      Discussion
    • 15:00 GMT+0
      Debate #2: Surveillance vs. Adjuvant Therapy: Are We Overtreating? Role of Biomarkers
    • 15:00 - 15:12 GMT+0
      Position 1: Adjuvant Therapy Should Be Standard for High-risk RCC

      Speaker: Mark Preston – Department of Urology, Brigham and Women's Hospital

    • 15:12 - 15:24 GMT+0
      Position 2: Active Surveillance is the Better Approach for Select Patients

      Speaker: Simpa S. Salami – University of Michigan

    • 15:24 - 15:30 GMT+0
      Discussion